Streetwise Biotech / Pharmaceuticals Articles

2017: A Year of Triple Digit Stock Performance
Source: Streetwise Reports  (12/28/17)
As stock indexes in the U.S. hit record highs in 2017, we take a look at some of the best performers profiled by Streetwise Reports in the last year, some of which have seen triple digit increases. More >

Biotech's Shares 'Undervalued' and Positioned for 'Long-Term Upside Potential'
Source: Streetwise Reports  (12/27/17)
Zacks Small-Cap Research analyst John Vandermosten reviewed the Q2 FY18 financial results for this epigenetics firm, which is moving forward with a Phase 3 trial targeting heart disease.
More >

Immunotherapy Firm Gets Green Light for Pivotal Trial From FDA
Source: Streetwise Reports  (12/27/17)
Jason Kolbert, an analyst with Maxim Group, described the study, which enables this biotech's device to be used in patients undergoing heart surgery and will measure its effectiveness in reducing a common post-surgical side effect.
More >

'Exciting' Collaborations Possible for Biotech's 'Flexible' Platform
Source: Streetwise Reports  (12/20/17)
Zacks Small-Cap Research's John Vandermosten discussed the potential for this immunotherapy firm's RNAi compounds in oncology. More >

Biotech Receives 'Major Endorsement from World-Leading Pharma Company'
Source: Streetwise Reports  (12/20/17)
David Kideckel, an analyst with Beacon Securities Ltd., relayed news from this firm's recent annual meeting, including a private placement with a large pharma and an update on the Phase 3 trial of its lead therapy. More >

Updates from ASH Reinforce Analyst's Big Price Target Potential
Source: Streetwise Reports  (12/20/17)
Andrew Fein, an analyst with H.C. Wainwright & Co., discussed the implications of this biopharmaceutical's recently announced data, which support his "bullish" outlook for the firm's candidate in chronic graft versus host disease.
More >

Cannabis Biotech Stock Starting to Advance Again
Source: Clive Maund for Streetwise Reports  (12/15/17)
A technical analysis by Clive Maund on has a Buy on this cannabis biotech stock. More >

'The Market Gets it Wrong, Again'; Analyst Raises Target Price on Biotech
Source: Streetwise Reports  (12/13/17)
Ed Arce, an analyst with H.C. Wainwright & Co., explained the positive elements of this drug developer's recently released clinical trial data and why they did not warrant the market reaction they got.
More >

Hunter Diamond

A New Breed of Regenerative Therapy Companies Taking Hold
Source: Hunter Diamond, CFA for Streetwise Reports  (12/7/17)
A regenerative therapy company with expertise in both cell therapy development and manufacturing, and a potential treatment for diabetes, differentiates this company, says Hunter Diamond, CFA, CEO of Diamond Equity Research. More >

John McCamant

Biotech Delivers 'Great' Phase 2 Data in NASH
Source: John McCamant for Streetwise Reports  (12/7/17)
John McCamant of the Medical Technology Stock Letter raised his target price on this company given the earning potential of a once-a-day oral treatment for liver disease in what could be a $35 billion market.
More >

Immuno-Oncology Candidate Yields 'Impressive' Early Clinical Results
Source: Streetwise Reports  (12/6/17)
This biotech reported positive results in a Phase 1b trial for its ovarian cancer immuno-oncology drug-delivery candidate, prompting increases in share price targets from a pair of analysts. More >

Coverage Initiated on 'One of the Most Undervalued Biotech Companies in Canada'
Source: Streetwise Reports  (12/6/17)
David Kideckel, an analyst with Beacon Securities Ltd., explained the investment thesis for this clinical-stage life sciences firm. More >

Biotech Advances Potential 'Billion-Dollar Drug' with New Trial Launch in China
Source: Streetwise Reports  (12/5/17)
Maxim Group analyst Jason Kolbert discussed what the launch of a clinical trial in China means for this developer of immuno-oncology therapies.
More >

Michael Sheikh

Drug in Combination with Merck's Blockbuster Keytruda Nearly Doubles Response Rate
Source: Michael Sheikh for Streetwise Reports  (12/4/17)
Michael Sheikh, the founder of Falcon Strategic Research, delves into a biotech company whose trial results he believes could fuel takeover speculation. More >

Potential Alzheimer's Therapies Focus on Early Intervention
Source: Streetwise Reports  (11/30/17)
After attending a conference on the latest in development of Alzheimer's disease treatments, Andrew Fein, an analyst with H.C. Wainwright & Co., provided an industry update. More >

Analyst's 'Top Pick' Advances Vaccine Candidates
Source: Streetwise Reports  (11/21/17)
Douglas Loe, an analyst with Echelon Wealth Partners, provided an update on this biotech's platform pipeline targeting ovarian and blood cancers, as well as respiratory syncytial virus. More >

Stock Price Jump Reflects Biotech's Active October
Source: Streetwise Reports  (11/20/17)
This immunotherapy firm's stock recently doubled its Nov. 7 price following lots of news, including a clinical data release, a trial launch and an executive appointment.
More >

Maxim's Target Price on Biotech Makes It More Than a Tenbagger
Source: Streetwise Reports  (11/20/17)
Jason Kolbert, an analyst with Maxim Group, provided an update on this biopharmaceutical firm's two recently acquired oncology assets.
More >

'Hot' Alzheimer's Market is Promising for Biotech with 'Novel' Drug Candidate
Source: Streetwise Reports  (11/20/17)
André Uddin, an analyst with Mackie Research Capital Corp., summarized the quarterly financial results and anticipated catalysts for this Alzheimer's drug developer.
More >

Biotech's Target Price Increased as Shares 'Deeply Undervalued'
Source: Streetwise Reports  (11/15/17)
Wedbush analyst Robert Driscoll provided an update on the lead asset of this drug developer targeting cancer.
More >

John McCamant

Biotech Targets 'Blockbuster' Markets; Less-Addictive Opioid Painkiller Set for FDA Filing
Source: John McCamant for Streetwise Reports  (11/15/17)
Medical Technology Stock Letter editor John McCamant outlines the reasons behind the buy rating and target price increases for a company that, in addition to developing an alternative to addictive opioids for pain relief, has candidates targeting multiple immune disorders and cancer.
More >

Analyst Says Biotech Share Price Could Potentially 'Double'
Source: Streetwise Reports  (11/13/17)
Analyst Grant Zeng of Zacks Small Cap Research examines what transpired with this biopharmaceutical company during Q3/17. More >

Biotech with Solid Pipeline and 'Solid Partnership Outlook'
Source: Streetwise Reports  (11/13/17)
Analyst Kevin DeGeeter, with Ladenburg Thalmann, relayed the highlights from his recent meeting with this company's management team about near-term clinical news and pipeline plans.
More >

Biotech Reports Positive Topline Data; Biologics License Application in Progress
Source: Streetwise Reports  (11/6/17)
Ram Selvaraju, an analyst with H.C. Wainwright & Co., reviewed the recent clinical trial results released by this developer of cell therapies targeting oncology and orphan indications.
More >

Target Price Raised on 'Undervalued' Antibiotics Developer
Source: Streetwise Reports  (11/6/17)
Analyst Ed Arce discussed the rationale behind H.C. Wainwright & Co.'s decision to revise its models on this clinical-stage biopharmaceutical company. More >

Showing Results: 26 to 50 of 722 Prev Next

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts

"VIVE's cash as of Q4/17 was $20.7M."
– Jeff Cohen, Ladenburg Thalmann
"For Q4/17, DRRX recorded revenue of $19.5M compared to $3.5M in Q4/16."
– Grant Zeng, Zacks Investment Research, Zacks Small-Cap Research